

Event alert | [Save the date](#) | [Details to follow](#)



September 11, 2014  
New York, NY

## Collectis R&D / Analyst Day

### Event Details

**Date:** September 11, 2014

**Time:** 8:00 AM

**Location:** Le Parker Meridien Hotel - 119 West 56th Street - NEW YORK

**Collectis' scientists will be attending in New York to present the Company's therapeutic innovations.**

### Our strengths:

- **State-of-the-art genome engineering technologies**
- **New CAR (Chimeric Antigen Receptor) architecture**
- **Allogeneic cGMP manufacturing process for CART products**

### Please RSVP with

Collectis / Jennifer Moore [jennifer.moore@collectis.com](mailto:jennifer.moore@collectis.com)

The Trout Group / Simon Harnest [sharnest@troutgroup.com](mailto:sharnest@troutgroup.com) – Phone : +1-646-378-2919

Upon invitation – limited seats available

### About Collectis

Collectis is a biopharmaceutical company focused on oncology. The company's mission is to develop a novel generation of therapy based on engineered T-cells to treat cancer. Collectis capitalizes on its 14 years of expertise in genome engineering, based on TALEN™, meganucleases and the state-of-the-art electroporation technology Pulse Agile, to create a new generation of cancer immunotherapy for treating leukemias and solid tumors. Collectis adoptive cancer immunotherapy for chronic and acute leukemias is based on the first allogeneic T-cell chimeric antigen receptor (CAR) technology. CAR technologies are designed to target surface antigens expressed on cells. These treatments reduce toxicities associated with current chemotherapeutics and have the potential for curative therapy. The Collectis Group is focused on life sciences and uses leading genome engineering technologies to build innovative products in various fields and markets. Collectis is listed on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: [www.collectis.com](http://www.collectis.com).